

## DAFTAR PUSTAKA

- Barylski, M., Nikfar, S., Mikhailidis, D.P., Toth, P.P., Salari, P., Ray, K.K., dkk., 2013. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. *Pharmacological Research*, **72**: 35–44.
- Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., dkk., 2015. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *The New England Journal of Medicine*, **372**: 2387–2397.
- Casula, M., Gazzotti, M., Bonaiti, F., Olmastroni, E., Arca, M., Averna, M., dkk., 2021. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. *Journal of Internal Medicine*, **290**: 116–128.
- Cho, L., Rocco, M., Colquhoun, D., Sullivan, D., Rosenson, R.S., Dent, R., dkk., 2016. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study. *Cardiovascular Drugs and Therapy*, **30**: 297–304.
- Csonka, C., Sárközy, M., Pipicz, M., Dux, L., dan Csont, T., 2016. Modulation of Hypercholesterolemia-Induced Oxidative/Nitrative Stress in the Heart. *Oxidative Medicine and Cellular Longevity*, **2016**: 3863726.
- Cziraky, M.J., Willey, V.J., McKenney, J.M., Kamat, S.A., Fisher, M.D., Guyton, J.R., dkk., 2013. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. *Journal of Clinical Lipidology*, **7**: 102–108.
- Damayanti, R., 2017. Buku Ajar Miopati. *Textbook of Myopathy*, **4**: 26-119.
- De Bleecker, J.L., 2005. How to approach the patient with muscular symptoms in the general neurological practice? *Acta Neurologica Belgica*, **105**: 18–22.
- Doughty, C.T. dan Amato, A.A., 2019. Toxic Myopathies. *Continuum (Minneapolis, Minn.)*, **25**: 1712–1731.
- Dubińska-Magiera, M., Migocka-Patrzałek, M., Lewandowski, D., Daczewska, M., dan Jagla, K., 2021. Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies. *International Journal of Molecular Sciences*, **22**: 5654.
- Fernandes, V., Santos, M.J., dan Pérez, A., 2016. Statin-related myotoxicity. *Endocrinología y Nutrición*, **63**: 239–249.
- Ferrari, M., Guasti, L., Maresca, A., Mirabile, M., Contini, S., Grandi, A.M., dkk., 2014. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. *European Journal of Clinical Pharmacology*, **70**: 539–547.
- Fung, E.C. dan Crook, M.A., 2012. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. *Cardiovascular Therapeutics*, **30**: e212-218.

- Gheorghe, G., Toth, P.P., Bungau, S., Behl, T., Ilie, M., Pantea Stoian, A., dkk., 2020. Cardiovascular Risk and Statin Therapy Considerations in Women. *Diagnostics (Basel, Switzerland)*, **10**: E483.
- Harikumar, K., S, A.A., B, K. kumar, M, R., dan H, S.C., 2013. A Review on Hyperlipidemic. *International Journal of Novel Trends in Pharmaceutical Sciences*, **3**: 59–71.
- Hopewell, J.C., Offer, A., Haynes, R., Bowman, L., Li, J., Chen, F., dkk., 2020. Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom. *European Heart Journal*, **41**: 3336–3342.
- Huang, Z., Li, Q., Ye, W., Zhang, Q., dan Li, X., 2019. Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. *Chemical & Pharmaceutical Bulletin*, **67**: 419–425.
- Ito, M.K., Maki, K.C., Brinton, E.A., Cohen, J.D., dan Jacobson, T.A., 2014. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study. *Journal of Clinical Lipidology*, **8**: 69–76.
- Joy, T.R. dan Hegele, R.A., 2009. Narrative review: statin-related myopathy. *Annals of Internal Medicine*, **150**: 858–868.
- Katsiki, N., Nikolic, D., Montalto, G., Banach, M., Mikhailidis, D.P., dan Rizzo, M., 2013. The role of fibrate treatment in dyslipidemia: an overview. *Current Pharmaceutical Design*, **19**: 3124–3131.
- Kemenkes, 2019. Laporan Nasional Riskesdas 2018. *Lembaga Penerbit Balitbangkes*, **26**: 4–12.
- Li, J.-J., Liu, H.-H., Wu, N.-Q., Yeo, K.K., Tan, K., Ako, J., dkk., 2020. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects. *Expert Opinion on Drug Metabolism & Toxicology*, **16**: 837–851.
- Mastaglia, F.L., 2020. The changing spectrum of drug-induced myopathies. *Acta Myologica: Myopathies and Cardiomyopathies: Official Journal of the Mediterranean Society of Myology*, **39**: 283–288.
- Morrone, D., Weintraub, W.S., Toth, P.P., Hanson, M.E., Lowe, R.S., Lin, J., dkk., 2012. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. *Atherosclerosis*, **223**: 251–261.
- Nanna, M.G., Navar, A.M., Giugliano, R.P., White, J.A., Lokhnygina, Y., Mitchel, Y.B., dkk., 2020. Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. *Journal of the American College of Cardiology*, **75**: 835–837.

- Nissen, S.E., Stroes, E., Dent-Acosta, R.E., Rosenson, R.S., Lehman, S.J., Sattar, N., dkk., 2016. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. *JAMA*, **315**: 1580–1590.
- PERKI, 2017. Pedoman Tatalaksana Dislipidemia 2017. *Perhimpunan Dokter Spesialis Kardiovaskular Indonesia*, **53**: 9-43.
- Rönnqvist, J., Hallberg, P., Yue, Q.-Y., dan Wadelius, M., 2018. Fusidic Acid: A Neglected Risk Factor for Statin-Associated Myopathy. *Clinical Medicine Insights. Cardiology*, **12**: 1179546818815162.
- Rosenson, R.S., Baker, S., Banach, M., Borow, K.M., Braun, L.T., Bruckert, E., dkk., 2017. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. *Journal of the American College of Cardiology*, **70**: 1290–1301.
- Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., dkk., 2017. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *The New England Journal of Medicine*, **376**: 1713–1722.
- Saxon, D.R. dan Eckel, R.H., 2016. Statin Intolerance: A Literature Review and Management Strategies. *Progress in Cardiovascular Diseases*, **59**: 153–164.
- Settergren, J., Eiermann, B., dan Mannheimer, B., 2013. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study. *PloS One*, **8**: e69545.
- Siriangkawut, M., Tansakul, P., dan Uchaipichat, V., 2017. Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction. *Saudi Pharmaceutical Journal : SPJ*, **25**: 823–829.
- Stule, T., Češka, R., dan Gotto, A.M., 2015. Statin Intolerance: the Clinician's Perspective. *Current Atherosclerosis Reports*, **17**: 69.
- Tariq, R.A., Vashisht, R., Sinha, A., dan Scherbak, Y., 2021. Medication Dispensing Errors And Prevention, *StatPearls*, **13**: 76-80.
- Thambiah, S., Meor Anuar Shuhaili, M.F.R., Chew, B.H., Samsudin, I.N., Abdul Rahman, H., Stanslas, J., dkk., 2019. A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort. *Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals*, **24**: 659–665.
- Tomaszewski, M., Stępień, K.M., Tomaszewska, J., dan Czuczwar, S.J., 2011. Statin-induced myopathies. *Pharmacological reports: PR*, **63**: 859–866.
- Wei, M.Y., Ito, M.K., Cohen, J.D., Brinton, E.A., dan Jacobson, T.A., 2013. Predictors of statin adherence, switching, and discontinuation in the



- USAGE survey: understanding the use of statins in America and gaps in patient education. *Journal of Clinical Lipidology*, **7**: 472–483.
- Whitfield, L.R., Porcari, A.R., Alvey, C., Abel, R., Bullen, W., dan Hartman, D., 2011. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. *Journal of Clinical Pharmacology*, **51**: 378–388.
- World Health Organization, 2014. Noncommunicable Diseases Country Profiles 2014. *World Health Organization*, **23**: 126–143.
- Yunita, E.P., Puspitasari, I., dan Tjahjono, C., 2021. Symptoms of Statin-Induced Adverse Drug Reactions on Muscle on Older Patients. *Tropical Journal of Natural Product Research*, **5**: 1234–1239.
- Zabihi, M., Askarian, F., Hekmatimoghaddam, S., Zabihi, M.S., dan Vahidi, F., 2021. Combination of atorvastatin and gemfibrozil plus physical activity: an animal model of statin/fibrate-induced myopathy. *Somatosensory & Motor Research*, **38**: 90–94.
- Zhang, H., Plutzky, J., Skentzos, S., Morrison, F., Mar, P., Shubina, M., dkk., 2013. Discontinuation of statins in routine care settings: a cohort study. *Annals of Internal Medicine*, **158**: 526–534.
- Zhang, X., Geng, P., Zhang, T., Lu, Q., Gao, P., dan Mei, J., 2020. Aceso: PICO-Guided Evidence Summarization on Medical Literature. *IEEE Journal of Biomedical and Health Informatics*, **24**: 2663–2670.